Cardiome jumps on fast-acting vernakalant; US filing plans still unknown
This article was originally published in Scrip
Executive Summary
Cardiome Pharma jumped 15.6% to close at $3.49 per share on 23 September after the company revealed data from an open-label study that showed patients in atrial fibrillation achieved conversion to normal sinus rhythm more than 10 times faster with intravenous vernakalant than with the oral therapies propafenone and flecainide.